Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

[1]  K. Schmid,et al.  Processing Escape Mechanisms Through Altered Proteasomal Cleavage of Epitopes Affect Immune Response in Pulmonary Neuroendocrine Tumors , 2018, Technology in Cancer Research & Treatment.

[2]  A. Bankfalvi,et al.  Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy , 2018, Pneumologie.

[3]  C. Hoang,et al.  In vitro experimental models of mesothelioma revisited. , 2017, Translational lung cancer research.

[4]  G. Matullo,et al.  Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. , 2017, Cancer letters.

[5]  R. Stahel,et al.  A Novel BRCA1‐Associated Protein‐1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1‐Mediated DNA Repair , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  R. Hromas,et al.  Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition , 2017, Cancer Chemotherapy and Pharmacology.

[7]  M. Carbone,et al.  Mesothelioma: recent highlights. , 2017, Annals of translational medicine.

[8]  K. Schmid,et al.  miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma , 2017, Virchows Archiv.

[9]  S. Emri.  The Cappadocia mesothelioma epidemic: its influence in Turkey and abroad. , 2017, Annals of translational medicine.

[10]  R. Zanetti,et al.  [TNM Classification of malignant tumours - Eighth edition: which news?] , 2017, Epidemiologia e prevenzione.

[11]  K. Schmid,et al.  Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy , 2016, Journal of Cancer.

[12]  M. Küçüköner,et al.  Comparison of SKIP expression in malignant pleural mesotheliomas with Ki-67 proliferation index and prognostic parameters. , 2016, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[13]  Min Zhang,et al.  Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. , 2016, Gynecologic Oncology.

[14]  F. Galateau-Sallé,et al.  The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Alan Ashworth,et al.  BRCAness revisited , 2016, Nature Reviews Cancer.

[16]  W. Eberhardt,et al.  Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements , 2014, Current opinion in oncology.

[17]  C. Wagner,et al.  The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review. , 2013, Anticancer research.

[18]  K. Gardner,et al.  BRCA1 and p53 regulate critical prostate cancer pathways , 2013, Prostate Cancer and Prostatic Diseases.

[19]  F. Hirsch,et al.  Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  A. Ashworth,et al.  The DNA damage response and cancer therapy , 2012, Nature.

[21]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[22]  C. Sander,et al.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma , 2011, Nature Genetics.

[23]  H. Pass,et al.  An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. , 2011, American journal of respiratory cell and molecular biology.

[24]  G. Wani,et al.  Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis , 2010, International journal of cancer.

[25]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[26]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[27]  A. Lau,et al.  4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. , 2008, Journal of medicinal chemistry.

[28]  F. Ardissone,et al.  Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[29]  Hans Joenje,et al.  Fanconi anemia and DNA replication repair. , 2007, DNA repair.

[30]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[31]  M. Byrne,et al.  Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  S. Jhanwar,et al.  Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma , 2001, Oncogene.

[33]  A. Ashworth,et al.  Mutation in Brca2 stimulates error‐prone homology‐directed repair of DNA double‐strand breaks occurring between repeated sequences , 2001, The EMBO journal.

[34]  G. Iliakis,et al.  Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Jasin,et al.  BRCA2 is required for homology-directed repair of chromosomal breaks. , 2001, Molecular cell.

[36]  S. Lundgren,et al.  pleural mesothelioma : Genome-wide expression patterns reflecting eneral resistance mechanisms and a proposal of novel targets luf , 2009 .

[37]  F. Ricceri,et al.  Survival of pleural malignant mesothelioma in Italy: A population‐based study , 2009, International journal of cancer.

[38]  A. D’Andrea,et al.  The Fanconi anaemia/BRCA pathway , 2003, Nature Reviews Cancer.